Amy Schumer Shares Experience with Mounjaro, Contrasting it with Previous Ozempic Struggles

Amy Schumer, the renowned comedian and actress, has recently opened up about her experience with Mounjaro, a weight-loss medication, and how it vastly differs from her previous encounter with Ozempic. In a video clip shared with her massive following of nearly 13 million on Instagram, Schumer, 43, praised the effects of Mounjaro (tirzepatide), highlighting the positive impact it has had on her well-being.

However, her journey with weight-loss medications hasn’t always been smooth sailing. Years ago, Schumer attempted to use Ozempic for weight loss but was forced to discontinue its use due to debilitating side effects that left her bedridden.

In the Instagram video, Schumer shared her past experience with Ozempic, admitting that it was "completely unsafe to be driving and making a video" while recounting the story. She stated, "Years ago, three years ago, I tried WeGovy and I was like puking. I couldn’t handle it. I don’t know if they’ve changed the formula or whatever."

Schumer then explained how she sought an alternative solution, stating, "I went on this telehealth meeting with MidiHealth, and it was cheap. I wanted to try it myself, cause I wanted to recommend it to my friends who are like nurses and teachers."

In addition to Mounjaro, Schumer revealed that her new routine also includes hormone therapy. "They put me on estrogen and progesterone because I realized I was in perimenopause and my symptoms of being in perimenopause have disappeared," she said. She elaborated on the positive effects of hormone therapy, stating, "My hair is fuller, my skin is better, I have more energy, I want to get down more if you know what I mean – I’m talking about sex. So that’s been great, Mounajro’s been great. I’m having a really good experience with it and I wanted to keep it real with you about that."

Schumer also disclosed that she was so impressed with MidiHealth that she decided to invest in the company. She concluded her video with a lighthearted remark, "I’m not going to stir the pot, but why don’t we have to call Kate Middleton Kate of Wales? Ok, Hilaria. Out."

Earlier this year, during an interview with Howard Stern, Schumer shed more light on her negative experience with Ozempic, explaining that she had to quit due to the severity of the side effects. She stated, "I have this gene – GDF15 – which makes you extremely prone to nausea which is why I was so sick during my pregnancy. So, I tried Ozempic almost three years ago and I was like bedridden, I was vomiting and then you have no energy but other people take it and they’re all good."

Schumer also acknowledged the rapid weight loss she experienced while on Ozempic, stating, "I lost 30 pounds so quick. I looked great and I couldn’t lift my head off the pillow, so what’s the point?"

Ozempic, containing semaglutide, was initially approved by the U.S. Food and Drug Administration (FDA) for the treatment of Type 2 diabetes. However, it has gained popularity as an off-label prescription for weight loss, along with other similar medications.

Mounjaro (tirzepatide), like Ozempic, is a medication initially designed for managing type 2 diabetes. It works by mimicking the effects of incretin hormones, which are naturally produced in the body and play a role in regulating blood sugar levels. Tirzepatide activates both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual action helps to increase insulin release, decrease glucagon secretion, slow down gastric emptying, and ultimately promote weight loss.

Ozempic functions primarily as a GLP-1 receptor agonist, stimulating insulin release and reducing appetite. While both medications share the common goal of managing blood sugar and aiding in weight loss, their mechanisms of action differ slightly, potentially influencing their side effect profiles.

The contrasting experiences of Amy Schumer with Ozempic and Mounjaro highlight the individual variability in response to these medications. Factors such as genetics, underlying health conditions, and lifestyle can influence how a person reacts to a particular drug. In Schumer’s case, the presence of the GDF15 gene, which predisposes her to nausea, likely contributed to the severe side effects she experienced with Ozempic.

It is crucial to consult with a qualified healthcare professional before considering any weight-loss medication. A doctor can assess an individual’s medical history, evaluate potential risks and benefits, and determine the most appropriate treatment plan. Self-treating with medications can be dangerous and may lead to adverse health consequences. Telehealth platforms like MidiHealth can provide convenient access to medical consultations, but they should not replace the care of a primary care physician or specialist.

The decision to use weight-loss medications should be made in conjunction with a comprehensive lifestyle approach that includes a balanced diet, regular exercise, and stress management techniques. Medications can be a helpful tool for some individuals, but they are not a magic bullet. Sustainable weight loss requires a holistic approach that addresses the underlying factors contributing to weight gain.